Venous Thromboembolism and Orthopedic Surgery

  • Anne R. BassEmail author


Thromboembolic events are common and feared complications of orthopedic surgery, particularly lower extremity arthroplasty. Both patient and procedure-related risk factors have been identified. Prevention, an important tenant of orthopedic care, involves pharmacologic, nonpharmacologic approaches. This chapter presents a general overview of the problem of thromboembolism in the orthopedic setting.


Venous thromboembolism Orthopedic surgery Pharmacologic approach Nonpharmacologic approach Risks Arthroplasty 


  1. 1.
    Kim J, Kraft P, Hagan KA, Harrington LB, Lindstroem S, Kabrhel C. Interaction of a genetic risk score with physical activity, physical inactivity, and body mass index in relation to venous thromboembolism risk. Genet Epidemiol. 2018;42(4):354–65.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Delluc A, Gourhant L, Lacut K, Mercier B, Audrezet M, Nowak E, et al. Association of common genetic variations and idiopathic venous thromboembolism. Results from EDITh, a hospital-based case-control study. Thromb Haemost. 2010;103(6):1161–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Crous-Bou M, Harrington LB, Kabrhel C. Environmental and genetic risk factors associated with venous thromboembolism. Semin Thromb Hemost. 2016;42(8):808–20.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Margaglione M, Grandone E. Population genetics of venous thromboembolism. A narrative review. Thromb Haemost. 2011;105(2):221–31.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost. 2009;7 Suppl 1:301–4.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Zhou X, Qian W, Li J, Zhang P, Yang Z, Chen W, et al. Who are at risk for thromboembolism after arthroplasty? A systematic review and meta-analysis. Thromb Res. 2013;132(5):531–6.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Newman JM, Abola MV, Macpherson A, Klika AK, Barsoum WK, Higuera CA. ABO blood group is a predictor for the development of venous thromboembolism after total joint arthroplasty. J Arthroplast. 2017;32(9S):S258.Google Scholar
  9. 9.
    Imberti D, Bianchi C, Zambon A, Parodi A, Merlino L, Gallerani M, et al. Venous thromboembolism after major orthopaedic surgery: a population-based cohort study. Intern Emerg Med. 2012;7(3):243–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Memtsoudis S, Liu SS, Ma Y, Chiu YL, Walz JM, Gaber-Baylis LK, et al. Perioperative pulmonary outcomes in patients with sleep apnea after noncardiac surgery. Anesth Analg. 2011;112(1):113–21.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007;44(2):62–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol. 2001;38(2 Suppl 5):12–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776–86.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90(3):446–55.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Albayati MA, Grover SP, Saha P, Lwaleed BA, Modarai B, Smith A. Postsurgical inflammation as a causative mechanism of venous thromboembolism. Semin Thromb Hemost. 2015;41(6):615–20.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Dahl OE, Pedersen T, Kierulf P, Westvik AB, Lund P, Arnesen H, et al. Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery. Thromb Res. 1993;70(6):451–8.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Sharrock NE, Go G, Harpel PC, Ranawat CS, Sculco TP, Salvati EA. The John Charnley Award. Thrombogenesis during total hip arthroplasty. Clin Orthop Relat Res. 1995;319:16–27.Google Scholar
  18. 18.
    Nishiguchi M, Takamura N, Abe Y, Kono M, Shindo H, Aoyagi K. Pilot study on the use of tourniquet: a risk factor for pulmonary thromboembolism after total knee arthroplasty? Thromb Res. 2005;115(4):271–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Turan A, Bajracharya GR, Leung S, Yazici Kara M, Mao G, Botsford T, et al. Association of neuraxial anesthesia with postoperative venous thromboembolism after noncardiac surgery: a propensity-matched analysis of ACS-NSQIP database. Anesth Analg. 2019;128(3):494–501.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Memtsoudis SG, González Della Valle A, Besculides MC, Gaber L, Sculco TP. In-hospital complications and mortality of unilateral, bilateral, and revision TKA: based on an estimate of 4,159,661 discharges. Clin Orthop Relat Res. 2008;466(11):2617–27.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Memtsoudis SG, Mantilla CB, Parvizi J, Stundner O, Mazumdar M. Have bilateral total knee arthroplasties become safer? A population-based trend analysis. Clin Orthop Relat Res. 2013;471(1):17–25.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Restrepo C, Parvizi J, Dietrich T, Einhorn TA. Safety of simultaneous bilateral total knee arthroplasty. A meta-analysis. J Bone Joint Surg Am. 2007;89(6):1220–6.CrossRefGoogle Scholar
  23. 23.
    Bounameaux H, Miron MJ, Blanchard J, de Moerloose P, Hoffmeyer P, Leyvraz PF. Measurement of plasma D-dimer is not useful in the prediction or diagnosis of postoperative deep vein thrombosis in patients undergoing total knee arthroplasty. Blood Coagul Fibrinolysis. 1998;9(8):749–52.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Sugimoto E, Kuroda T, Fujita Y, Namba Y, Mitani S. D-dimer testing cannot rule out thromboembolism after major lower extremity arthroplasties and thromboprophylaxis treatment. J Anesth. 2015;29(5):686–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster diagnostic imaging practice guidelines initiative. Ann Intern Med. 1998;128(8):663–77.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Hull R, Hirsh J, Sackett DL, Powers P, Turpie AG, Walker I, et al. N Engl J Med. 1977;296(26):1497–500.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Palareti G, Cosmi B, Legnani C. Diagnosis of deep vein thrombosis. Semin Thromb Hemost. 2006;32(7):659–72.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Song K, Xu Z, Rong Z, Yang X, Yao Y, Shen Y, et al. The incidence of venous thromboembolism following total knee arthroplasty: a prospective study by using computed tomographic pulmonary angiography in combination with bilateral lower limb venography. Blood Coagul Fibrinolysis. 2016;27(3):266–9.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    van der Hulle T, Cheung WY, Kooij S, Beenen LFM, van Bemmel T, van Es J, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet. 2017;390(10091):289–97.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Pena E, Kimpton M, Dennie C, Peterson R, LE Gal G, Carrier M. Difference in interpretation of computed tomography pulmonary angiography diagnosis of subsegmental thrombosis in patients with suspected pulmonary embolism. J Thromb Haemost. 2012;10(3):496–8.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Carrier M, Righini M, Wells PS, Perrier A, Anderson DR, Rodger MA, et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost. 2010;8(8):1716–22.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    den Exter PL, van Es J, Klok FA, Kroft LJ, Kruip Marieke JHA, Kamphuisen PW, et al. Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood. 2013;122(7):1149; quiz 1329.Google Scholar
  33. 33.
    Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):453S.Google Scholar
  35. 35.
    Lotke PA, Palevsky H, Keenan AM, Meranze S, Steinberg ME, Ecker ML, et al. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop Relat Res. 1996;324:251–8.CrossRefGoogle Scholar
  36. 36.
    Haas SB, Tribus CB, Insall JN, Becker MW, Windsor RE. The significance of calf thrombi after total knee arthroplasty. J Bone Joint Surg Br. 1992;74(6):799–802.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest. 2009 Feb;135(2):513–20.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    AAOS. We recommend against routine post-operative duplex ultrasonography screening of patients who undergo elective hip or knee arthroplasty. 2015.; Available at: Accessed 03 May 2018.
  39. 39.
    Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e325S.Google Scholar
  40. 40.
    Kearon C. Noninvasive diagnosis of deep vein thrombosis in postoperative patients. Semin Thromb Hemost. 2001;27(1):3–8.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med. 1998;158(8):873–8.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Robinson KS, Anderson DR, Gross M, Petrie D, Leighton R, Stanish W, et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med. 1997;127(6):439–45.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Elbuluk AM, Kim KY, Chen KK, Anoushiravani AA, Schwarzkopf R, Iorio R. Respiratory synchronized versus intermittent pneumatic compression in prevention of venous thromboembolism after total joint arthroplasty: a systematic review and meta-analysis. Orthop Clin North Am. 2018;49(2):123–33.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Hardwick ME, Pulido PA, Colwell CW. A mobile compression device compared with low-molecular-weight heparin for prevention of venous thromboembolism in total hip arthroplasty. Orthop Nurs. 2011;30(5):312–6.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Eisele R, Kinzl L, Koelsch T. Rapid-inflation intermittent pneumatic compression for prevention of deep venous thrombosis. J Bone Joint Surg Am. 2007;89(5):1050–6.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Pagella P, Cipolle M, Sacco E, Matula P, Karoly E, Bokovoy J. A randomized trial to evaluate compliance in terms of patient comfort and satisfaction of two pneumatic compression devices. Orthop Nurs. 2007;26(3):169–74.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Edwards JZ, Pulido PA, Ezzet KA, Copp SN, Walker RH, Colwell CW. Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty. J Arthroplast. 2008;23(8):1122–7.CrossRefGoogle Scholar
  48. 48.
    Nakamura M, Kamei M, Bito S, Migita K, Miyata S, Kumagai K, et al. Spinal anesthesia increases the risk of venous thromboembolism in total arthroplasty: Secondary analysis of a J-PSVT cohort study on anesthesia. Medicine (Baltimore). 2017;96(18):e6748.CrossRefGoogle Scholar
  49. 49.
    Haas S, Holberg G, Kreutz R, Lassen MR, Mantovani L, Haupt V, et al. The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery – subgroup analyses from 17,701 patients in the XAMOS study. Vasc Health Risk Manag. 2016;12:209–18.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Rosencher N, Noack H, Feuring M, Clemens A, Friedman RJ, Eriksson BI. Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials. Thromb J. 2012;10(1):9.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e496S.Google Scholar
  52. 52.
    Mismetti P, Laporte S, Pellerin O, Ennezat P, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA. 2015;313(16):1627–35.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Bass AR, Mattern CJ, Voos JE, Peterson MG, Trost DW. Inferior vena cava filter placement in orthopedic surgery. Am J Orthop (Belle Mead NJ). 2010;39(9):435–9.Google Scholar
  54. 54.
    Stern JR, Cafasso DE, Meltzer AJ, Schneider DB, Ellozy SH, Connolly PH. Prophylactic inferior vena cava filter utilization and risk factors for nonretrieval. Vasc Endovasc Surg. 2018;52(1):34–8.CrossRefGoogle Scholar
  55. 55.
    Young T, Tang H, Hughes R. Vena caval filters for the prevention of pulmonary embolism. Cochrane Database Syst Rev. 20107;2:CD006212.Google Scholar
  56. 56.
    Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338(7):409–15.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Shah M, Alnabelsi T, Patil S, Reddy S, Patel B, Lu M, et al. IVC filters-Trends in placement and indications, a study of 2 populations. Medicine (Baltimore). 2017;96(12):e6449.CrossRefGoogle Scholar
  58. 58.
    Anderson FA, Huang W, Friedman RJ, Kwong LM, Lieberman JR, Pellegrini VD, et al. Prevention of venous thromboembolism after hip or knee arthroplasty: findings from a 2008 survey of US orthopedic surgeons. J Arthroplast. 2012;27(5):666.e5.CrossRefGoogle Scholar
  59. 59.
    Berry DJ, Bozic KJ. Current practice patterns in primary hip and knee arthroplasty among members of the American Association of Hip and Knee Surgeons. J Arthroplast. 2010;25(6 Suppl):2–4.CrossRefGoogle Scholar
  60. 60.
    Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA. 2016;316(20):2115–25.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Anderson DR, Wilson SJ, Blundell J, Petrie D, Leighton R, Stanish W, et al. Comparison of a nomogram and physician-adjusted dosage of warfarin for prophylaxis against deep-vein thrombosis after arthroplasty. J Bone Joint Surg Am. 2002;84-A(11):1992–7.CrossRefGoogle Scholar
  62. 62.
    Asnis PD, Gardner MJ, Ranawat A, Leitzes AH, Peterson MGE, Bass AR. The effectiveness of warfarin dosing from a nomogram compared with house staff dosing. J Arthroplast. 2007;22(2):213–8.CrossRefGoogle Scholar
  63. 63.
    Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. JAMA. 2017;318(12):1115–24.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823–33.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Working Party, Association of Anaesthetists of Great Britain & Ireland, Obstetric Anaesthetists’ Association, Regional Anaesthesia UK. Regional anaesthesia and patients with abnormalities of coagulation: the Association of Anaesthetists of Great Britain & Ireland The Obstetric Anaesthetists’ Association Regional Anaesthesia UK. Anaesthesia. 2013;68(9):966–72.CrossRefGoogle Scholar
  66. 66.
    Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK, Kopp SL, Benzon HT, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med. 2010;35(1):64–101.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397–402.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Adam SS, McDuffie JR, Lachiewicz PF, Ortel TL, Williams JW. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. Ann Intern Med. 2013;159(4):275–84.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Rose DK, Bar B. Direct oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents. J Stroke Cerebrovasc Dis. 2018;27(8):2049–58.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Tornkvist M, Smith JG, Labaf A. Current evidence of oral anticoagulant reversal: a systematic review. Thromb Res. 2018;162:22–31.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Holzmacher JL, Sarani B. Indications and methods of anticoagulation reversal. Surg Clin North Am. 2017;97(6):1291–305.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Salvati EA, Sharrock NE, Westrich G, Potter HG, Valle AGD, Sculco TP. The 2007 ABJS Nicolas Andry Award: three decades of clinical, basic, and applied research on thromboembolic disease after THA: rationale and clinical results of a multimodal prophylaxis protocol. Clin Orthop Relat Res. 2007;459:246–54.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Lalmohamed A, Vestergaard P, de Boer A, Leufkens HGM, van Staa TP, de Vries F. Changes in mortality patterns following total hip or knee arthroplasty over the past two decades: a nationwide cohort study. Arthritis Rheum (Hoboken, NJ). 2014;66(2):311–8.CrossRefGoogle Scholar
  74. 74.
    Kulshrestha V, Kumar S. DVT prophylaxis after TKA: routine anticoagulation vs risk screening approach – a randomized study. J Arthroplast. 2013;28(10):1868–73.CrossRefGoogle Scholar
  75. 75.
    Zou Y, Tian S, Wang Y, Sun K. Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. Blood Coagul Fibrinolysis. 2014;25(7):660–4.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Sharrock NE, Gonzalez Della Valle A, Go G, Lyman S, Salvati EA. Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res. 2008;466(3):714–21.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Sobieraj DM, Lee S, Coleman CI, Tongbram V, Chen W, Colby J, et al. Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review. Ann Intern Med. 2012;156(10):720–7.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355(9212):1295–302.Google Scholar
  79. 79.
    Westrich GH, Bottner F, Windsor RE, Laskin RS, Haas SB, Sculco TP. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. J Arthroplast. 2006;21(6 Suppl 2):139–43.CrossRefGoogle Scholar
  80. 80.
    Jiang Y, Du H, Liu J, Zhou Y. Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. Chin Med J. 2014;127(12):2201–5.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158(11):800–6.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018;378(8):699–707.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765–75.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487–98.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Hur M, Park S, Koo C, Jung ED, Kang P, Kim WH, et al. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty. Acta Orthop. 2017;88(6):634–41.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Venker BT, Ganti BR, Lin H, Lee ED, Nunley RM, Gage BF. Safety and efficacy of new anticoagulants for the prevention of venous thromboembolism after hip and knee arthroplasty: a meta-analysis. J Arthroplast. 2017;32(2):645–52.CrossRefGoogle Scholar
  87. 87.
    Jameson SS, Rymaszewska M, Hui ACW, James P, Serrano-Pedraza I, Muller SD. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg Am. 2012;94(17):1554–8.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178–85.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949–56.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Pan P, Lin P, Tang G, Lan T. Comparisons of mortality and rehospitalization between hip-fractured elderly with outpatient rehabilitation and those without: a STROBE-compliant article. Medicine (Baltimore). 2018;97(19):e0644.CrossRefGoogle Scholar
  91. 91.
    Frisch NB, Wessell N, Charters M, Greenstein A, Shaw J, Peterson E, et al. Hip fracture mortality: differences between intertrochanteric and femoral neck fractures. J Surg Orthop Adv. 2018;27(1):64–71.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Li Q, Dai B, Xu J, Yao Y, Song K, Zhang H, et al. Can patients with femoral neck fracture benefit from preoperative thromboprophylaxis?: a prospective randomized controlled trial. Medicine (Baltimore). 2017;96(29):e7604.CrossRefGoogle Scholar
  93. 93.
    Zheng G, Tang Q, Shang P, Pan X, Liu H. No effectiveness of anticoagulants for thromboprophylaxis after non-major knee arthroscopy: a systemic review and meta-analysis of randomized controlled trials. J Thromb Thrombolysis. 2018;45(4):562–70.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Schairer WW, Pedtke AC, Hu SS. Venous thromboembolism after spine surgery. Spine. 2014;39(11):911–8.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Sebastian AS, Currier BL, Kakar S, Nguyen EC, Wagie AE, Habermann ES, et al. Risk factors for venous thromboembolism following thoracolumbar surgery: analysis of 43,777 patients from the American College of Surgeons National Surgical Quality Improvement Program 2005 to 2012. Global Spine J. 2016;6(8):738–43.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Du W, Zhao C, Wang J, Liu J, Shen B, Zheng Y. Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery. J Orthop Surg Res. 2015;10:78.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Sansone JM, del Rio AM, Anderson PA. The prevalence of and specific risk factors for venous thromboembolic disease following elective spine surgery. J Bone Joint Surg Am. 2010;92(2):304–13.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Bryson DJ, Uzoigwe CE, Braybrooke J. Thromboprophylaxis in spinal surgery: a survey. J Orthop Surg Res. 2012;7:14.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Simioni P, et al. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial. Ann Intern Med. 2008;149(2):73–82.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    van Adrichem RA, Nemeth B, Algra A, le Cessie S, Rosendaal FR, Schipper IB, et al. Thromboprophylaxis after knee arthroscopy and lower-leg casting. N Engl J Med. 2017;376(6):515–25.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Imberti D, Ivaldo N, Murena L, Paladini P, Castagna A, Barillari G, et al. Venous thromboembolism in patients undergoing shoulder surgery: findings from the RECOS Registry. Thromb Res. 2014;134(2):273–7.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Jameson SS, Augustine A, James P, Serrano-Pedraza I, Oliver K, Townshend D, et al. Venous thromboembolic events following foot and ankle surgery in the English National Health Service. J Bone Joint Surg Br. 2011;93(4):490–7.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Navarro RA, Inacio MCS, Burke MF, Costouros JG, Yian EH. Risk of thromboembolism in shoulder arthroplasty: effect of implant type and traumatic indication. Clin Orthop Relat Res. 2013;471(5):1576–81.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Huntley SR, Abyar E, Lehtonen EJ, Patel HA, Naranje S, Shah A. Incidence of and risk factors for venous thromboembolism after foot and ankle surgery. Foot Ankle Spec. 2019;12(3):218–27.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Fleischer AE, Abicht BP, Baker JR, Boffeli TJ, Jupiter DC, Schade VL. American College of Foot and Ankle Surgeons’ clinical consensus statement: risk, prevention, and diagnosis of venous thromboembolism disease in foot and ankle surgery and injuries requiring immobilization. J Foot Ankle Surg. 2015;54(3):497–507.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993;329(19):1370–6.CrossRefPubMedPubMedCentralGoogle Scholar
  107. 107.
    Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002;59(9319):1721–6.CrossRefGoogle Scholar
  108. 108.
    Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345(18):1298–304.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594–604.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Medicine, Division of RheumatologyHospital for Special Surgery, Weill Cornell MedicineNew YorkUSA

Personalised recommendations